ONO-2952

DRUG5 trials

Sponsors

Ono Pharma USA Inc

Conditions

HealthyHealthy Adult SubjectsIrritable Bowel Syndrome (IBS)

Phase 1

Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

CompletedNCT01364441

Ono Pharma USA IncHealthy Adult Subjects

Start: 2011-05-31Updated: 2012-06-13

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

CompletedNCT01489345

Ono Pharma USA IncHealthy

Start: 2011-12-31Updated: 2012-08-01

ONO-2952 Single-dose PET Study in Healthy Adult Subjects

CompletedNCT01613703

Ono Pharma USA IncHealthy Adult Subjects

Start: 2012-08-31Updated: 2013-06-03

Phase 2

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

CompletedNCT01844180

Ono Pharma USA IncIrritable Bowel Syndrome (IBS)

Start: 2013-04-30Updated: 2016-04-15

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

TerminatedNCT01887002

Ono Pharma USA IncIrritable Bowel Syndrome (IBS)

Start: 2013-06-30Updated: 2016-02-25

Related Papers

Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome

UNC Libraries2020-03-261 citations

Randomised clinical trial: exploratory phase 2 study of <scp>ONO</scp> ‐2952 in diarrhoea‐predominant irritable bowel syndrome

Alimentary Pharmacology & Therapeutics2016-11-0719 citations

Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.

2015-08-049 citations